Sulfasalazine Use During Pregnancy

Safety Profile and Recommendations

• The European League Against Rheumatism (EULAR) recommends sulfasalazine as a pregnancy-compatible conventional synthetic disease-modifying antirheumatic drug (csDMARD) at doses up to 2 g/day, with concomitant daily folic acid supplementation due to its inhibition of folate absorption 1, 2
• Current evidence does not indicate an increased rate of congenital malformations or other adverse pregnancy outcomes with sulfasalazine use during pregnancy 2

Dosing and Administration

• The maximum recommended dose of sulfasalazine during pregnancy is 2 g/day, according to the EULAR recommendations 1, 2
• Folic acid supplementation is essential when using sulfasalazine during pregnancy due to its inhibition of folate absorption, with a recommended dose of 1 mg daily 2, 3
• Folic acid supplementation should be started at least 3 months before conception and continued throughout pregnancy 4

Clinical Considerations and Monitoring

• For patients with inflammatory bowel disease (IBD), sulfasalazine has been shown to be safe during pregnancy with no increased risk of adverse pregnancy outcomes compared to the general population 3

Comparative Safety Among Antirheumatic Drugs

• Sulfasalazine is considered safe during pregnancy, unlike methotrexate, leflunomide, and mycophenolate, which are teratogenic and contraindicated during pregnancy 2
• Sulfasalazine belongs to the same safety category as hydroxychloroquine, azathioprine, cyclosporine, tacrolimus, and colchicine, all considered compatible with pregnancy 1, 2